Machine Medicine is building a data and AI operating system for neurotech, using tools like video, wearables, and machine learning to make neurological symptoms measurable and treatments more precise.

Mendi has built a consumer brain-training headband using fNIRS, grounding neurofeedback in peer-reviewed research while turning cognitive training into a daily, gamified habit.

Coherence Neuro is advancing an implantable BCI that uses electrical stimulation and sensing to disrupt tumor activity and monitor brain cancer in real time.

Connectome Health is bringing research-grade brain imaging into consumer settings, offering short cortical scans to establish cognitive baselines and support a shift toward preventative brain health.

Subsense is developing a nanoparticle-based brain-computer interface delivered through the nose, aiming to modulate brain activity without surgery and reduce reliance on implanted electrodes.

Non-invasive brain stimulation has existed for decades, but its application to women’s cognitive health has lagged behind. A new neurotech venture is adapting tDCS to address menstrual-related cognitive and emotional symptoms.

A former touring DJ is translating years of experience shaping mental states through sound into a new kind of neurotechnology, exploring how audio and visuals might support focus, calm, and cognitive resilience.

Many amputees abandon advanced prosthetics because control is unintuitive or invasive. A new startup is rethinking bionic limbs around non-invasive brain signals, affordability, and everyday usability.

A new generation of neurotech founders is emerging earlier than ever. With personal stakes and a DIY mindset, a student-led team is applying brain–computer interfaces to one of epilepsy’s most persistent challenges.

As neuroscience revisits its electrical roots, a new generation of multimodal imaging is bringing timing and structure back together. Combining EEG and fMRI may offer a clearer view of brain network disorders.

From academic lab work to biotech leadership, a new generation of founders is rethinking how brain drugs are discovered. Patient-derived organoids and AI are beginning to reshape what’s possible in CNS therapeutics.